Cargando…

Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?

PURPOSE: To provide a reference for clinicians, whether patients with advanced ovarian clear cell carcinoma (OCCC) require chemotherapy (CT) for more than 6 cycles after tumor debulking. PATIENTS AND METHODS: A retrospective review was performed on 85 women diagnosed and treated for advanced OCCC. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Shi, Yuying, Liu, Yan, Li, Wei, Jiang, Hong, Cai, Hongbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671476/ https://www.ncbi.nlm.nih.gov/pubmed/33223852 http://dx.doi.org/10.2147/CMAR.S280141

Ejemplares similares

Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
por: Seol, Aeran, et al.
Publicado: (2022)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis
por: Yang, Ya’nan, et al.
Publicado: (2015)

Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study
por: Gao, Yang
Publicado: (2023)

Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
por: Shi, Tingyan, et al.
Publicado: (2019)

The Role of Chemotherapy in the Survival Benefits of Patients Aged Older Than 40 Years With Osteosarcoma
por: Cao, Zhiyou, et al.
Publicado: (2021)

Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles: Based on a retrospective and observational study of follow-up within 3 years of 843 patients
por: Li, Yifan, et al.
Publicado: (2022)

Residual Tumor Diameter Predicts Progression After Primary Debulking Surgery of Ovarian Clear Cell Carcinoma (OCCC): Clinicopathologic Study of Stage II-IV OCCC Patients from a Single Institution
por: Shi, Yuying, et al.
Publicado: (2021)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis
por: Kim, Se Ik, et al.
Publicado: (2019)

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer
por: Peters-Engl, C, et al.
Publicado: (1999)

Cell phones give more benefits than risks, but…
por: Słojewski, Marcin
Publicado: (2013)

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
por: Lakhani, S., et al.
Publicado: (1990)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Survivability Is More Fundamental Than Evolvability
por: Palmer, Michael E., et al.
Publicado: (2012)

Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial
por: Qi, Yuwen, et al.
Publicado: (2022)

Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer
por: Matsuo, Koji, et al.
Publicado: (2019)

Long-term antibiotics in COPD: more benefit than harm?
por: Miravitlles, Marc
Publicado: (2013)

More than Just Wine: The Nutritional Benefits of Grapevine Leaves
por: Maia, Marisa, et al.
Publicado: (2021)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Pectoralis block for breast surgeries: More than postoperative analgesic
por: Bakshi, Sumitra G, et al.
Publicado: (2019)

Survival analysis, more than meets the eye
por: Lucijanic, Marko, et al.
Publicado: (2017)

Survival benefit of pancreatic metastasectomy of clear cell renal cell carcinoma
por: Fang, Yuan, et al.
Publicado: (2019)

The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours
por: Kajiyama, Hiroaki, et al.
Publicado: (2018)

Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles
por: Bull, Jonathan R., et al.
Publicado: (2019)

Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction
por: Mandai, Masaki, et al.
Publicado: (2015)

A Review of the Benefits of Nature Experiences: More Than Meets the Eye
por: Franco, Lara S., et al.
Publicado: (2017)

Benefits of fading in perceptual learning are driven by more than dimensional attention
por: Wisniewski, Matthew G., et al.
Publicado: (2017)

Commentary: Diagnosing ovarian cancer—more problems than answers
por: Fox, Robin
Publicado: (2009)

A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report
por: Yamaguchi, Hironori, et al.
Publicado: (2016)

No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients
por: Li, Feng, et al.
Publicado: (2021)

Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy
por: Zhou, Yun, et al.
Publicado: (2018)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy
por: Chen, Chu-Ying, et al.
Publicado: (2022)

Aspirin use correlates with survival in women with clear cell ovarian cancer
por: Wield, Alyssa M., et al.
Publicado: (2018)

Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
por: Jin, Yin, et al.
Publicado: (2021)

Eccentric cycling is more efficient in reducing fat mass than concentric cycling in adolescents with obesity
por: Julian, Valérie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8siv2fgcu611e0eo9kvcj26923